Siglec15 overexpression correlated with shorter survival time in patients with nasopharyngeal adenocarcinoma and glioblastoma, receiving immunotherapy, and showed a trend in urothelial cancer (Supplementary Fig. 8H–J).
← all excerpts
Evasion of immunosurveillance by the upregulation of Siglec15 in bladder cancer.
1
—
—